Clinical Trials
115 trialsDose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma
M.D. Anderson Cancer Center
Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas
Thomas Jefferson University
Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma
National Cancer Institute (NCI)
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Istari Oncology, Inc.
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
National Cancer Institute (NCI)
HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors
University of Alabama at Birmingham
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
SCRI Development Innovations, LLC
Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme
Canadian Cancer Trials Group
EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas
Columbia University
Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma
Center Trials & Treatment Europe
ATTAC
Duke University
BG & TMZ Therapy of Glioblastoma Multiforme
Case Comprehensive Cancer Center
Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Cancer Institute (NCI)
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab
Stanford University
REGULATe
Duke University
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
Biogen
Vaccine Therapy in Treating Patients With Malignant Glioma
Jonsson Comprehensive Cancer Center
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
Jonsson Comprehensive Cancer Center
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
Case Comprehensive Cancer Center
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Lumos Pharma
Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Virginia Commonwealth University
Gene Therapy in Treating Patients With Primary Brain Tumors
Abramson Cancer Center at Penn Medicine
TARGET-I
DNAtrix, Inc.
Tumor Tissue Analysis in Patients Receiving Imatinib Mesylate for Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
O(6)-Benzylguanine in Treating Patients With Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gene Therapy in Treating Patients With Recurrent Malignant Gliomas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gadolinium Texaphyrin Plus Radiation Therapy in Treating Patients With Supratentorial Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma
Ohio State University Comprehensive Cancer Center
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
City of Hope Medical Center
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
City of Hope Medical Center
Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma
Cancer Research UK
A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas
City of Hope Medical Center
Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma
City of Hope Medical Center
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
Pediatric Brain Tumor Consortium
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
Roswell Park Cancer Institute
Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme
Duke University
Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
Abramson Cancer Center at Penn Medicine
ZAP IT
Duke University
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Duke University
Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Cancer Research UK
Vaccine Therapy in Treating Patients With Malignant Glioma
Jonsson Comprehensive Cancer Center
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
National Cancer Institute (NCI)
Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)
Merck Sharp & Dohme LLC
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
City of Hope Medical Center